Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules

Data from the prospective, multi-center, intra-patient controlled trial showed a fusion rate for MagnetOs of 78%, compared to 42% for autograft. This compares favorably to fusion rates of 55-71% reported for other synthetic bone grafts evaluated in similar well-controlled studies of posterolateral fusion.1,2

The first consecutive 50 patients (from a total of 100) requiring up to four-level instrumented posterolateral lumbar fusion (T10 – S2), were included in this preliminary analysis. The rate of posterolateral lumbar/thoracolumbar fusion was assessed by CT-scan 12 months after surgery. Data can  be downloaded from the Kuros website.

Joost de Bruijn, Chief Executive Officer of Kuros, said: “We are pleased to complete enrolment in the trial and take another step forward in the clinical phase of Project Fusion with MagnetOs, with the aim of delivering the ideal bone graft. Previous bone grafts have been sold on the premise of improved clinical outcomes but based on benchtop or preclinical data, so we are excited to demonstrate MagnetOs’ effect in a high-level clinical setting. This further demonstrates our commitment to converting our ground-breaking research to Level 1 evidence of efficacy in humans, and to fund research in spine surgery for the benefit of patients, surgeons, and our wider society.”